Positron emission tomography imaging of prostate cancer

Amino Acids

Volumn 39, Issue 1, 2010, Pages 11-27

  Hong, Hao ^a   Zhang, Yin ^a   Sun, Jiangtao ^a   Cai, Weibo ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antibody; Molecular imaging; Peptide; Positron emission tomography; Prostate cancer

Indexed keywords

CARBON 11; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; GASTRIN RELEASING PEPTIDE RECEPTOR; LEUCINE; METHIONINE; PROSTATE STEM CELL ANTIGEN; TRACER; TRYPTOPHAN; VITRONECTIN RECEPTOR;

AMINO ACID TRANSPORT; BONE METASTASIS; CANCER DIAGNOSIS; CELL MEMBRANE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FATTY ACID SYNTHESIS; HUMAN; ISOTOPE LABELING; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 77953616376     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-009-0394-9     Document Type: Review

References (144)

1. S Agrawal KP Patil WD Dunsmuir 2009 Molecular markers in prostate cancer. Part II: potential roles in management Asian J Androl 11 22 27 1:CAS:528:DC%2BD1MXnvFCru7w%3D 19050689 10.1038/aja.2008.23
2. 11C-acetate PET in the early evaluation of prostate cancer recurrence Eur J Nucl Med Mol Imaging 34 185 196 16832632 10.1007/s00259-006-0163-x (Pubitemid 46147501)
3. A Al-Nahhas Z Win T Szyszko A Singh S Khan D Rubello 2007 What can gallium-68 PET add to receptor and molecular imaging? Eur J Nucl Med Mol Imaging 34 1897 1901 17713764 10.1007/s00259-007-0568-1 (Pubitemid 350212142)
4. HJ Ananias IJ De Jong RA Dierckx C van de Wiele W Helfrich PH Elsinga 2008 Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals Curr Pharm Des 14 3033 3047 1:CAS:528: DC%2BD1MXmt1ehug%3D%3D 18991717 10.2174/138161208786404335
5. AB Apolo N Pandit-Taskar MJ Morris 2008 Novel tracers and their development for the imaging of metastatic prostate cancer J Nucl Med 49 2031 2041 18997047 10.2967/jnumed.108.050658
6. RJ Barren III EH Holmes AL Boynton SL Misrock GP Murphy 1997 Monoclonal antibody 7E11.C5 staining of viable LNCaP cells Prostate 30 65 68 9018338 10.1002/(SICI)1097-0045(19970101)30:1<65::AID-PROS10>3.0.CO;2-N (Pubitemid 27053543)
7. MF Bartholdi JM Wu H Pu P Troncoso PA Eden RI Feldman 1998 In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma Int J Cancer 79 82 90 1:STN:280:DyaK1c7lsVOmsA%3D%3D 9495364 10.1002/(SICI)1097-0215(19980220)79:1<82::AID-IJC16>3.0.CO;2-J (Pubitemid 28157732)
8. M Beheshti R Vali P Waldenberger F Fitz M Nader W Loidl G Broinger F Stoiber I Fogelman W Langsteger 2008 Detection of bone metastases in patients with prostate cancer by F-18 fluorocholine and F-18 fluoride PET-CT: a comparative study Eur J Nucl Med Mol Imaging 35 1766 1774 18465129 10.1007/s00259-008-0788-z
9. GB Biddlecombe BE Rogers M de Visser JJ Parry M De Jong JL Erion JS Lewis 2007 Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1, Tyr4)-bombesin(1-14) Bioconjug Chem 18 724 730 1:CAS:528:DC%2BD2sXjtlCnu7Y%3D 17378600 10.1021/bc060281l (Pubitemid 47010791)
10. K Bouchelouche P Oehr 2008 Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review J Urol 179 34 45 1:CAS:528:DC%2BD1cXnslygug%3D%3D 17997425 10.1016/j.juro.2007.08.176 (Pubitemid 350225698)
11. SA Brassell IL Rosner DG McLeod 2005 Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer Curr Opin Urol 15 163 166 15815192 10.1097/01.mou.0000165549.94663.2d
12. R Brissette NI Goldstein 2007 The use of phage display peptide libraries for basic and translational research Methods Mol Biol 383 203 213 1:CAS:528:DC%2BD2sXhtleru7zP 18217687 10.1007/978-1-59745-335-6-13
13. 3 antagonism Anticancer Agents Med Chem 6 407 428 1:CAS:528:DC%2BD28Xos1Gqt7w%3D 17017851 10.2174/187152006778226530
14. 3 Cancer Res 66 9673 9681 1:CAS:528:DC%2BD28XhtVams73J 17018625 10.1158/0008-5472.CAN-06-1480 (Pubitemid 44623667)
15. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody Eur J Nucl Med Mol Imaging 34 850 858 1:CAS:528:DC%2BD2sXltl2htLo%3D 17262214 10.1007/s00259-006-0361-6 (Pubitemid 46798960)
16. W Cai A Ebrahimnejad K Chen Q Cao ZB Li DA Tice X Chen 2007 Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice Eur J Nucl Med Mol Imaging 34 2024 2036 1:CAS:528:DC%2BD2sXhtlyiurzO 17673999 10.1007/s00259-007-0503-5 (Pubitemid 350212123)
17. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody J Nucl Med 48 304 310 1:CAS:528:DC%2BD2sXhsVSitrzL 17268029 10.2967/jnumed.107.043216 (Pubitemid 350099333)
18. W Cai G Niu X Chen 2008 Imaging of integrins as biomarkers for tumor angiogenesis Curr Pharm Des 14 2943 2973 1:CAS:528:DC%2BD1MXmt1ehsQ%3D%3D 18991712 10.2174/138161208786404308
19. W Cai G Niu X Chen 2008 Multimodality imaging of the HER-kinase axis in cancer Eur J Nucl Med Mol Imaging 35 186 208 17846765 10.1007/s00259-007-0560-9 (Pubitemid 350234146)
20. RE Carter AR Feldman JT Coyle 1996 Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase Proc Natl Acad Sci USA 93 749 753 1:CAS:528:DyaK28XnslOksA%3D%3D 8570628 10.1073/pnas.93.2.749 (Pubitemid 26041162)
21. R Cescato T Maina B Nock A Nikolopoulou D Charalambidis V Piccand JC Reubi 2008 Bombesin receptor antagonists may be preferable to agonists for tumor targeting J Nucl Med 49 318 326 1:CAS:528:DC%2BD1cXivVOltb8%3D 18199616 10.2967/jnumed.107.045054 (Pubitemid 351225672)
22. SS Chang VE Reuter WD Heston NH Bander LS Grauer PB Gaudin 1999 Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res 59 3192 3198 1:CAS:528:DyaK1MXksVCqtbs%3D 10397265
23. 3]bombesin in human prostate adenocarcinoma xenografts J Nucl Med 45 1390 1397 1:CAS:528:DC%2BD2cXnsFSlsr4%3D 15299066
24. DB Cornelio R Roesler G Schwartsmann 2007 Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy Ann Oncol 18 1457 1466 1:STN:280:DC%2BD2srgvFenuw%3D%3D 17351255 10.1093/annonc/mdm058 (Pubitemid 47365477)
25. FL Cury G Shenouda L Souhami M Duclos SL Faria M David F Verhaegen R Corns T Falco 2006 Ultrasound-based image guided radiotherapy for prostate cancer: comparison of cross-modality and intramodality methods for daily localization during external beam radiotherapy Int J Radiat Oncol Biol Phys 66 1562 1567 17056194
26. 11C-choline PET: first clinical experience Eur J Nucl Med Mol Imaging 29 1283 1288 12271408 10.1007/s00259-002-0881-7 1:CAS:528:DC%2BD38Xnt1Ggu7g%3D (Pubitemid 44392207)
27. 18F-labeled choline analogs J Nucl Med 48 1225 17607041 10.2967/jnumed.107.040667 (Pubitemid 47052664)
28. F Dehdashti J Picus JM Michalski CS Dence BA Siegel JA Katzenellenbogen MJ Welch 2005 Positron tomographic assessment of androgen receptors in prostatic carcinoma Eur J Nucl Med Mol Imaging 32 344 350 15726353 10.1007/s00259-005- 1764-5 (Pubitemid 40562127)
29. 18F-labeled deoxyglucose J Urol 155 994 998 1:STN:280: DyaK287msVKnug%3D%3D 8583625 10.1016/S0022-5347(01)66366-3 (Pubitemid 26052696)
30. MA Eisenberger BA Blumenstein ED Crawford G Miller DG McLeod PJ Loehrer G Wilding K Sears DJ Culkin IM Thompson Jr AJ Bueschen BA Lowe 1998 Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N Engl J Med 339 1036 1042 1:CAS:528:DyaK1cXmvV2itr8%3D 9761805 10.1056/ NEJM199810083391504 (Pubitemid 28457865)
31. KM Emonds JV Swinnen L Mortelmans FM Mottaghy 2009 Molecular imaging of prostate cancer Methods 48 193 199 1:CAS:528:DC%2BD1MXmvFymtbw%3D 19362147 10.1016/j.ymeth.2009.03.021
32. B Eriksson M Bergstrom A Lilja H Ahlstrom B Langstrom K Oberg 1993 Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors Acta Oncol 32 189 196 1:STN:280:DyaK3szht1Grsw%3D%3D 7686763 10.3109/02841869309083911
33. V Erspamer GF Erpamer M Inselvini 1970 Some pharmacological actions of alytesin and bombesin J Pharm Pharmacol 22 875 876 1:CAS:528: DyaE3MXjtVKmsQ%3D%3D 4395815
34. 11C-choline PET/CT with histopathologic step-section analysis J Nucl Med 46 1642 1649 1:CAS:528:DC%2BD28XitVGlt74%3D 16204714
35. M Farsad R Schiavina A Franceschelli F Sanguedolce P Castellucci A Bertaccini E Brunocilla F Manferrari S Concetti M Garofalo C Rocca M Borghesi R Franchi S Fanti C Nanni G Martorana 2008 Positron-emission tomography in imaging and staging prostate cancer Cancer Biomark 4 277 284 1:STN:280: DC%2BD1cnptFKqsQ%3D%3D 18957716
36. D Filpula 2007 Antibody engineering and modification technologies Biomol Eng 24 201 215 1:CAS:528:DC%2BD2sXls1SjsLg%3D 17466589 10.1016/j.bioeng.2007.03. 004 (Pubitemid 46755015)
37. CA Foss RC Mease H Fan Y Wang HT Ravert RF Dannals RT Olszewski WD Heston AP Kozikowski MG Pomper 2005 Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer Clin Cancer Res 11 4022 4028 1:CAS:528:DC%2BD2MXks1Gksr0%3D 15930336 10.1158/1078-0432.CCR-04-2690 (Pubitemid 40791565)
38. S Froidevaux AN Eberle 2002 Somatostatin analogs and radiopeptides in cancer therapy Biopolymers 66 161 183 1:CAS:528:DC%2BD38Xos1ahs7c%3D 12385036 10.1002/bip.10256 (Pubitemid 35285217)
39. M Fuchsjager A Shukla-Dave O Akin J Barentsz H Hricak 2008 Prostate cancer imaging Acta Radiol 49 107 120 1:STN:280:DC%2BD1c%2FlsFagtQ%3D%3D 18210320 10.1080/02841850701545821
40. SS Gambhir 2002 Molecular imaging of cancer with positron emission tomography Nat Rev Cancer 2 683 693 1:CAS:528:DC%2BD38Xmslanu7c%3D 12209157 10.1038/nrc882 (Pubitemid 37328919)
41. SS Gambhir J Czernin J Schwimmer DH Silverman RE Coleman ME Phelps 2001 A tabulated summary of the FDG PET literature J Nucl Med 42 1S 93S 1:STN:280:DC%2BD3Mvjs1Wgtw%3D%3D 11483694
42. 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems J Nucl Med 48 1327 1337 1:CAS:528:DC%2BD2sXhtVSktbzP 17631556 10.2967/jnumed.107.039487 (Pubitemid 47242799)
43. G Gasser L Tjioe B Graham MJ Belousoff S Juran M Walther JU Kunstler R Bergmann H Stephan L Spiccia 2008 Synthesis, copper(II) complexation, 64Cu-labeling, and bioconjugation of a new bis(2-pyridylmethyl) derivative of 1, 4, 7-triazacyclononane Bioconjug Chem 19 719 730 1:CAS:528:DC%2BD1cXhs1emt78%3D 18254581 10.1021/bc700396e (Pubitemid 351436371)
44. MM Goodman JL Devinney GW Kabalka 1994 Microprocessor-controlled open vessel system for the production of no-carrier-added-1-aminocyclobutane-1- carboxylic acid J Labelled Comp Radiopharm 35 331 333
45. Z Gu G Thomas J Yamashiro IP Shintaku F Dorey A Raitano ON Witte JW Said M Loda RE Reiter 2000 Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer Oncogene 19 1288 1296 1:CAS:528:DC%2BD3cXit1Krsb0%3D 10713670 10.1038/sj.onc.1203426
46. M Gugger JC Reubi 1999 Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast Am J Pathol 155 2067 2076 1:CAS:528:DC%2BD3cXit1Knsg%3D%3D 10595936
47. 18F- fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging J Nucl Med 43 187 199 1:CAS:528:DC%2BD38XjvFWjtrs%3D 11850483
48. CA Heinlein C Chang 2004 Androgen receptor in prostate cancer Endocr Rev 25 276 308 1:CAS:528:DC%2BD2cXktFSqtLY%3D 15082523 10.1210/er.2002-0032 (Pubitemid 38501396)
49. GH Hinkle JK Burgers CE Neal JH Texter D Kahn RD Williams R Maguire B Rogers JO Olsen RA Badalament 1998 Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide Cancer 83 739 747 1:STN:280:DyaK1cznt1Kksg%3D%3D 9708939 10.1002/(SICI)1097-0142(19980815)83:4<739::AID-CNCR16>3.0.CO;2-T (Pubitemid 28387698)
50. H Hricak PL Choyke SC Eberhardt SA Leibel PT Scardino 2007 Imaging prostate cancer: a multidisciplinary perspective Radiology 243 28 53 17392247 10.1148/radiol.2431030580 (Pubitemid 46579693)
51. KF Hubner S Krauss LC Washburn WD Gibbs EC Holloway 1981 Tumor detection with 1-aminocyclopentane and 1-aminocyclobutane C-11-carboxylic acid using positron emission computerized tomography Clin Nucl Med 6 249 252 1:STN:280:DyaL3M7oslSrtQ%3D%3D 6971725 10.1097/00003072-198106000-00004 (Pubitemid 11125759)
52. 18F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 253 263 17926036 10.1007/s00259-007-0552-9
53. AB Jani TH Fox D Whitaker DM Schuster 2009 Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design Clin Nucl Med 34 279 284 19387202 10.1097/RLU.0b013e31819e51e3
54. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin 58 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
55. M Jennewein MA Lewis D Zhao E Tsyganov N Slavine J He L Watkins VD Kodibagkar S O'Kelly P Kulkarni PP Antich A Hermanne F Rosch RP Mason PE Thorpe 2008 Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine Clin Cancer Res 14 1377 1385 1:CAS:528:DC%2BD1cXislSrs7s%3D 18316558 10.1158/1078-0432.CCR-07-1516 (Pubitemid 351413918)
56. KM Kalkner C Ginman S Nilsson M Bergstrom G Antoni H Ahlstrom B Langstrom JE Westlin 1997 Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma Nucl Med Biol 24 319 325 1:STN:280:DyaK2svgtFGltg%3D%3D 9257330 10.1016/S0969-8051(97)00064-4 (Pubitemid 27294674)
57. 13C MR spectroscopy J Nucl Med 49 341 344 1:CAS:528:DC%2BD1cXktlOnsrg%3D 18322118 10.2967/jnumed.107.045112 (Pubitemid 351355216)
58. LA Landon J Zou SL Deutscher 2004 Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol 1 113 132 1:CAS:528:DC%2BD2cXlt1Olsrk%3D 16472251 10.2174/1570163043335108
59. SM Larson H Schoder 2008 Advances in positron emission tomography applications for urologic cancers Curr Opin Urol 18 65 70 18090493 10.1097/MOU.0b013e3282f19cde (Pubitemid 350307534)
60. 18F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 366 373 1:CAS:528:DC%2BD2cXivVCjuro%3D 15001675
61. JB Lattouf R Srinivasan PA Pinto WM Linehan L Neckers 2006 Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy Nat Clin Pract Urol 3 590 601 1:CAS:528:DC%2BD28Xht12qtLzL 17088927 10.1038/ncpuro0604 (Pubitemid 44698094)
62. P Laverman OC Boerman FH Corstens WJ Oyen 2002 Fluorinated amino acids for tumour imaging with positron emission tomography Eur J Nucl Med Mol Imaging 29 681 690 1:CAS:528:DC%2BD38XkvFSns7Y%3D 11976809 10.1007/s00259-002-0856-8 (Pubitemid 34591703)
63. M Lebl J Hachmann 2005 High-throughput peptide synthesis Methods Mol Biol 298 167 194 1:CAS:528:DC%2BD2MXktlehtb8%3D 16044547
64. CS Levin EJ Hoffman 1999 Calculation of positron range and its effect on the fundamental limit of positron emission tomography system spatial resolution Phys Med Biol 44 781 799 1:STN:280:DyaK1M3is1OqsA%3D%3D 10211810 10.1088/0031-9155/44/3/019 (Pubitemid 29133069)
65. JS Lewis CJ Anderson 2007 Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy Methods Mol Biol 386 227 240 1:CAS:528:DC%2BD2sXmvVOitLY%3D 18604948 10.1007/978-1-59745-430-8-8
66. JV Leyton T Olafsen EJ Lepin S Hahm KB Bauer RE Reiter AM Wu 2008 Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors Clin Cancer Res 14 7488 7496 1:CAS:528: DC%2BD1cXhtlylurzE 19010866 10.1158/1078-0432.CCR-07-5093
67. JV Leyton T Olafsen MA Sherman KB Bauer P Aghajanian RE Reiter AM Wu 2009 Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors Protein Eng Des Sel 22 209 216 1:CAS:528: DC%2BD1MXit1Oitbw%3D 18957406 10.1093/protein/gzn055
68. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging J Nucl Med 49 453 461 1:CAS:528:DC%2BD1cXktlOns7o%3D 18287274 10.2967/jnumed.107.048009 (Pubitemid 351355212)
69. RA Linden EJ Halpern 2007 Advances in transrectal ultrasound imaging of the prostate Semin Ultrasound CT MR 28 249 257 17874649 10.1053/j.sult.2007.05. 002 (Pubitemid 47187637)
70. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging Epub
71. 18F-FB- PEG3-Glu-RGD-BBN J Med Chem 52 425 432 1:CAS:528:DC%2BD1MXnt1Kg 19113865 10.1021/jm801285t
72. CJ Logothetis NM Navone SH Lin 2008 Understanding the biology of bone metastases: key to the effective treatment of prostate cancer Clin Cancer Res 14 1599 1602 1:CAS:528:DC%2BD1cXjtlejtr4%3D 18347159 10.1158/1078-0432.CCR-07-4603 (Pubitemid 351469442)
73. HA Macapinlac JL Humm T Akhurst I Osman K Pentlow C Shangde HW Yeung O Squire RD Finn HI Scher SM Larson 1999 Differential metabolism and pharmacokinetics of L-[1-11C]-methionine and 2-[18F] fluoro-2-deoxy-D-glucose (FDG) in androgen independent prostate cancer Clin Positron Imaging 2 173 181 14516541 10.1016/S1095-0397(99)00015-1
74. M Mammen S Chio GM Whitesides 1998 Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors Angew Chem Int Ed Engl 37 2755 2794 1:CAS:528:DyaK1cXnsVGmsLs%3D 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
75. MJ Manyak 2008 Indium-111 capromab pendetide in the management of recurrent prostate cancer Expert Rev Anticancer Ther 8 175 181 1:CAS:528:DC%2BD1cXitlOgtrk%3D 18279057 10.1586/14737140.8.2.175 (Pubitemid 351385907)
76. R Markwalder JC Reubi 1999 Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation Cancer Res 59 1152 1159 1:CAS:528:DyaK1MXhslertrc%3D 10070977
77. D Mathews OK Oz 2002 Positron emission tomography in prostate and renal cell carcinoma Curr Opin Urol 12 381 385 12172424 10.1097/00042307-200209000- 00003
78. J McConathy MM Goodman 2008 Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography Cancer Metastasis Rev 27 555 573 18648909 10.1007/s10555-008-9154-7
79. TJ McDonald H Jornvall G Nilsson M Vagne M Ghatei SR Bloom V Mutt 1979 Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue Biochem Biophys Res Commun 90 227 233 1:CAS:528:DyaE1MXlslShsbY%3D 496973 10.1016/0006-291X(79)91614-0 (Pubitemid 10242631)
80. RC Mease CL Dusich CA Foss HT Ravert RF Dannals J Seidel A Prideaux JJ Fox G Sgouros AP Kozikowski MG Pomper 2008 N-[N-[(S)-1, 3-Dicarboxypropyl] carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer Clin Cancer Res 14 3036 3043 1:CAS:528:DC%2BD1cXmtVCmtb8%3D 18483369 10.1158/1078-0432.CCR-07-1517
81. 11C-glycylsarcosine, targeted to H +/peptide transporter J Nucl Med 49 615 622 1:CAS:528:DC%2BD1cXltl2gtLY%3D 18344442 10.2967/jnumed.107.048231 (Pubitemid 351520610)
82. MJ Morris T Akhurst I Osman R Nunez H Macapinlac K Siedlecki D Verbel L Schwartz SM Larson HI Scher 2002 Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 59 913 918 12031380 10.1016/S0090-4295(02)01509-1 (Pubitemid 34522186)
83. MJ Morris T Akhurst SM Larson M Ditullio E Chu K Siedlecki D Verbel G Heller WK Kelly S Slovin L Schwartz HI Scher 2005 Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy Clin Cancer Res 11 3210 3216 1:CAS:528:DC%2BD2MXjslOqsb4%3D 15867215 10.1158/1078-0432.CCR-04-2034 (Pubitemid 40627867)
84. UG Mueller-Lisse MG Swanson DB Vigneron J Kurhanewicz 2007 Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score Eur Radiol 17 371 378 16791635 10.1007/s00330-006-0321-3 (Pubitemid 46140308)
85. 18F- acetate PET in prostate cancer: may a choice be recommended? Eur J Nucl Med Mol Imaging 34 1704 1705 17619877 10.1007/s00259-007-0491-5 (Pubitemid 47476932)
86. V Nargund D Al Hashmi P Kumar S Gordon U Otitie D Ellison M Carroll S Baithun KE Britton 2005 Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging BJU Int 95 1232 1236 15892807 10.1111/j.1464-410X.2005.05511.x (Pubitemid 40799436)
87. G Niu W Cai K Chen X Chen 2008 Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor Mol Imaging Biol 10 99 106 18157579 10.1007/s11307-007-0123-2
88. G Niu W Cai X Chen 2008 Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression Front Biosci 13 790 805 1:CAS:528:DC%2BD1cXhs1ChtLs%3D 17981588 10.2741/2720 (Pubitemid 351599782)
89. M Norberg L Egevad L Holmberg P Sparen BJ Norlen C Busch 1997 The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer Urology 50 562 566 1:STN:280:DyaK2svnvVCrsw%3D%3D 9338732 10.1016/S0090-4295(97)00306-3 (Pubitemid 27433216)
90. N Normanno A De Luca C Bianco L Strizzi M Mancino MR Maiello A Carotenuto G De Feo F Caponigro DS Salomon 2006 Epidermal growth factor receptor (EGFR) signaling in cancer Gene 366 2 16 1:CAS:528:DC%2BD28Xht1Crs7k%3D 16377102 10.1016/j.gene.2005.10.018 (Pubitemid 43199589)
91. 11C- methionine PET scans in patients with newly progressive metastatic prostate cancer J Nucl Med 43 46 55 11801702
92. 18F-FACBC in humans J Nucl Med 48 1017 1020 1:CAS:528: DC%2BD2sXhtVertL7M 17504867 10.2967/jnumed.107.040097 (Pubitemid 46909932)
93. S Oka R Hattori F Kurosaki M Toyama LA Williams W Yu JR Votaw Y Yoshida MM Goodman O Ito 2007 A preliminary study of anti-1-amino-3-18F- fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer J Nucl Med 48 46 55 1:CAS:528:DC%2BD2sXhvFKmsbw%3D 17204698
94. SM Okarvi 2001 Recent progress in fluorine-18 labelled peptide radiopharmaceuticals Eur J Nucl Med 28 929 938 1:CAS:528:DC%2BD3MXkvVWltbg%3D 11504093 10.1007/s002590100508 (Pubitemid 32663907)
95. T Olafsen Z Gu MA Sherman JV Leyton ME Witkosky JE Shively AA Raubitschek SL Morrison AM Wu RE Reiter 2007 Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody J Immunother 30 396 405 1:CAS:528:DC%2BD2sXksFOlsbg%3D 17457214 10.1097/CJI.0b013e318031b53b (Pubitemid 46684429)
96. SJ Otto HJ de Koning 2004 Update on screening and early detection of prostate cancer Curr Opin Urol 14 151 156 15069305 10.1097/00042307-200405000- 00003 (Pubitemid 38582313)
97. N Oyama DE Ponde C Dence J Kim YC Tai MJ Welch 2004 Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation J Nucl Med 45 519 525 1:CAS:528:DC%2BD2cXivVCisr4%3D 15001697
98. JJ Parry TS Kelly R Andrews BE Rogers 2007 In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties Bioconjug Chem 18 1110 1117 1:CAS:528:DC%2BD2sXlt1Ogsr4%3D 17503761 10.1021/bc0603788 (Pubitemid 47122631)
99. EK Pauwels MJ Ribeiro JH Stoot VR McCready M Bourguignon B Maziere 1998 FDG accumulation and tumor biology Nucl Med Biol 25 317 322 1:CAS:528: DyaK1cXjtV2ksbo%3D 9639291 10.1016/S0969-8051(97)00226-6 (Pubitemid 28219093)
100. ME Phelps 2000 PET: the merging of biology and imaging into molecular imaging J Nucl Med 41 661 681 1:STN:280:DC%2BD3c3ivFSmtw%3D%3D 10768568
101. ME Phelps EJ Hoffman SC Huang MM Ter-Pogossian 1975 Effect of positron range on spatial resolution J Nucl Med 16 649 652 1:CAS:528:DyaE2MXlsFCgtL4%3D 1151485
102. J Pinski TB Dorff 2005 Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy Eur J Cancer 41 932 940 15808959 10.1016/j.ejca.2004.12.026 (Pubitemid 40461693)
103. C Plathow WA Weber 2008 Tumor cell metabolism imaging J Nucl Med 49 Suppl 2 43S 63S 1:CAS:528:DC%2BD1cXotFahurk%3D 18523065 10.2967/jnumed.107.045930 (Pubitemid 351948036)
104. 11C-acetate J Nucl Med 48 420 428 1:CAS:528:DC%2BD2sXhtVertLzL 17332620
105. AF Prasanphanich PK Nanda TL Rold L Ma MR Lewis JC Garrison TJ Hoffman GL Sieckman SD Figueroa CJ Smith 2007 [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues Proc Natl Acad Sci USA 104 12462 12467 1:CAS:528:DC%2BD2sXos1ehtLw%3D 17626788 10.1073/pnas.0705347104 (Pubitemid 47206160)
106. JM Price AJ Davidson 1979 Computed tomography in the evaluation of the suspected carcinomatous prostate Urol Radiol 1 39 42 1:STN:280: DyaL3M%2FotVGkug%3D%3D 95425 10.1007/BF02926598
107. JC Reader 2004 Automation in medicinal chemistry Curr Top Med Chem 4 671 686 1:CAS:528:DC%2BD2cXjtVeisr8%3D 15032681 10.2174/1568026043451069 (Pubitemid 38842584)
108. RE Reiter Z Gu T Watabe G Thomas K Szigeti E Davis M Wahl S Nisitani J Yamashiro MM Le Beau M Loda ON Witte 1998 Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer Proc Natl Acad Sci USA 95 1735 1740 1:CAS:528:DyaK1cXht1WqurY%3D 9465086 10.1073/pnas.95.4.1735 (Pubitemid 28103463)
109. JC Reubi 2007 Targeting CCK receptors in human cancers Curr Top Med Chem 7 1239 1242 1:CAS:528:DC%2BD2sXptFKgur8%3D 17584145 10.2174/156802607780960546 (Pubitemid 47040510)
110. JC Reubi HR Maecke 2008 Peptide-based probes for cancer imaging J Nucl Med 49 1735 1738 1:CAS:528:DC%2BD1cXhsVOhtLbP 18927341 10.2967/jnumed.108.053041
111. BE Rogers CJ Anderson JM Connett LW Guo WB Edwards EL Sherman KR Zinn MJ Welch 1996 Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism Bioconjug Chem 7 511 522 1:CAS:528:DyaK28XjvFequrY%3D 8853465 10.1021/bc9600372 (Pubitemid 26312142)
112. 64Cu-labeled bombesin analogue Bioconjug Chem 14 756 763 1:CAS:528:DC%2BD3sXkslymtb8%3D 12862428 10.1021/bc034018l (Pubitemid 36875435)
113. J Rorvik S Haukaas 2001 Magnetic resonance imaging of the prostate Curr Opin Urol 11 181 188 1:STN:280:DC%2BD3MzotFOmsw%3D%3D 11224749 10.1097/00042307-200103000-00009 (Pubitemid 32179399)
114. J Schlessinger 2000 Cell signaling by receptor tyrosine kinases Cell 103 211 225 1:CAS:528:DC%2BD3cXns1Cltrs%3D 11057895 10.1016/S0092-8674(00)00114-8
115. FH Schroder HB Carter T Wolters RC Van Den Bergh C Gosselaar CH Bangma MJ Roobol 2008 Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics Eur Urol 53 468 477 17997011 10.1016/j.eururo.2007.10.047 (Pubitemid 351179007)
116. DM Schuster JR Votaw PT Nieh W Yu JA Nye V Master FD Bowman MM Issa MM Goodman 2007 Initial experience with the radiotracer anti-1-amino-3-18F- fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma J Nucl Med 48 56 63 1:CAS:528:DC%2BD2sXhvFKmsb0%3D 17204699
117. MA Seltzer Z Barbaric A Belldegrun J Naitoh F Dorey ME Phelps SS Gambhir CK Hoh 1999 Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer J Urol 162 1322 1328 1:STN:280:DyaK1MvhvF2gug%3D%3D 10492189 10.1016/S0022-5347(05)68277-8 (Pubitemid 29428572)
118. Y Seo BL Franc RA Hawkins KH Wong BH Hasegawa 2006 Progress in SPECT/CT imaging of prostate cancer Technol Cancer Res Treat 5 329 336 16866563
119. RM Sharkey TM Cardillo EA Rossi CH Chang H Karacay WJ McBride HJ Hansen ID Horak DM Goldenberg 2005 Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody Nat Med 11 1250 1255 1:CAS:528:DC%2BD2MXhtFOhsLvL 16258537 10.1038/nm1322 (Pubitemid 43093674)
120. 18F]1-amino-3- fluorocyclobutane-1-carboxylic acid to image brain tumors J Nucl Med 40 331 338 1:CAS:528:DyaK1MXivVGlsr0%3D 10025843
121. DA Silver I Pellicer WR Fair WD Heston C Cordon-Cardo 1997 Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res 3 81 85 1:STN:280:DyaK1M%2FjsFamtA%3D%3D 9815541
122. DB Sodee AD Nelson PF Faulhaber GT Maclennan MI Resnick G Bakale 2005 Update on fused capromab pendetide imaging of prostate cancer Clin Prostate Cancer 3 230 238 1:CAS:528:DC%2BD2MXlslejurk%3D 15882479
123. DB Solit HI Scher N Rosen 2003 Hsp90 as a therapeutic target in prostate cancer Semin Oncol 30 709 716 1:CAS:528:DC%2BD3sXpt1Gksbk%3D 14571418 10.1016/S0093-7754(03)00346-4 (Pubitemid 37296795)
124. E Squillaci G Manenti S Mancino M Carlani M Di Roma V Colangelo G Simonetti 2005 MR spectroscopy of prostate cancer. Initial clinical experience J Exp Clin Cancer Res 24 523 530 1:CAS:528:DC%2BD28XhsFaqsbw%3D 16471314
125. 11C] methylaminoisobutyric acid, a tracer for PET studies on system A amino acid transport in vivo Eur J Nucl Med 28 847 854
126. SD Sweat A Pacelli GP Murphy DG Bostwick 1998 Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases Urology 52 637 640 1:STN:280:DyaK1cvjsVSnug%3D%3D 9763084 10.1016/S0090-4295(98)00278-7 (Pubitemid 28440171)
127. JH Texter Jr CE Neal 1998 The role of monoclonal antibody in the management of prostate adenocarcinoma J Urol 160 2393 2395 9817390 10.1016/S0022-5347(01)62197-9
128. IM Thompson DP Ankerst 2007 Prostate-specific antigen in the early detection of prostate cancer CMAJ 176 1853 1858 17576986
129. 11C]MeAIB, a new tracer for imaging of system A amino acid transport Eur J Nucl Med Mol Imaging 33 1178 1184 1:CAS:528:DC%2BD28XhtVahurvI 16721566 10.1007/s00259-006-0096-4 (Pubitemid 44484474)
130. 11C-methionine positron emission tomography J Urol 173 66 69 15592030 discussion 69
131. DG Udugamasooriya SP Dineen RA Brekken T Kodadek 2008 A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity J Am Chem Soc 130 5744 5752 1:CAS:528:DC%2BD1cXktFShsbc%3D 18386897 10.1021/ja711193x (Pubitemid 351600507)
132. M Uttamchandani SQ Yao 2008 Peptide microarrays: next generation biochips for detection, diagnostics and high-throughput screening Curr Pharm Des 14 2428 2438 1:CAS:528:DC%2BD1cXhtlehsb%2FL 18781992 10.2174/138161208785777450
133. AL Vavere JS Lewis 2008 Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines Nucl Med Biol 35 273 279 1:CAS:528:DC%2BD1cXjs1Kit7g%3D 18355682 10.1016/j.nucmedbio.2007.11.012 (Pubitemid 351381965)
134. AL Vavere SJ Kridel FB Wheeler JS Lewis 2008 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer J Nucl Med 49 327 334 1:CAS:528:DC%2BD1cXivVOltb0%3D 18199615 10.2967/jnumed.107.046672 (Pubitemid 351225673)
135. RE Weiner ML Thakur 2005 Radiolabeled peptides in oncology: role in diagnosis and treatment BioDrugs 19 145 163 1:CAS:528:DC%2BD2MXpt1eksrw%3D 15984900 10.2165/00063030-200519030-00002 (Pubitemid 40994231)
136. AM Wu PD Senter 2005 Arming antibodies: prospects and challenges for immunoconjugates Nat Biotechnol 23 1137 1146 1:CAS:528:DC%2BD2MXpvVyrtrk%3D 16151407 10.1038/nbt1141 (Pubitemid 41486395)
137. 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma Nucl Med Biol 33 371 380 1:CAS:528: DC%2BD28Xjs1GktrY%3D 16631086 10.1016/j.nucmedbio.2005.12.011
138. 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer J Nucl Med 45 1966 1971 1:CAS:528:DC%2BD2cXhtVKnurrL 15534070
139. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer J Nucl Med 47 492 501 1:CAS:528:DC%2BD28Xlt1Kmsb4%3D 16513619
140. 18F-FRGD2 J Nucl Med 47 113 121 1:CAS:528:DC%2BD28XhsFeisL4%3D 16391195 (Pubitemid 46768520)
141. H Zhang J Schuhmacher B Waser D Wild M Eisenhut JC Reubi HR Maecke 2007 DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours Eur J Nucl Med Mol Imaging 34 1198 1208 17262215 10.1007/s00259-006-0347-4 (Pubitemid 47296770)
142. H Zhuang JQ Yu A Alavi 2005 Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders Radiol Clin North Am 43 121 134 15693652 10.1016/j.rcl.2004.07.005 (Pubitemid 40326564)
143. S Zitzmann W Mier A Schad R Kinscherf V Askoxylakis S Kramer A Altmann M Eisenhut U Haberkorn 2005 A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy Clin Cancer Res 11 139 146 1:CAS:528: DC%2BD2MXhtVegsrw%3D 15671538
144. D Zwanziger IU Khan I Neundorf S Sieger L Lehmann M Friebe L Dinkelborg AG Beck-Sickinger 2008 Novel chemically modified analogues of neuropeptide Y for tumor targeting Bioconjug Chem 19 1430 1438 1:CAS:528:DC%2BD1cXns1SqtLY%3D 18572959 10.1021/bc7004297 (Pubitemid 352032343)